News & Events

Results of Operations and Financial Condition. On April 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the first quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this

Results of Operations and Financial Condition. On February 5, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the fourth quarter of 2025 and full year of 2025. A copy of the Earnings Press Release is furnished pursuant to this

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025. Ms. Leung is expected to remain with the Company for a transition period until her successor’s appointment in order to assist with the transition of her dutie…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On March 13, 2024, Mr. Gerald Storch notified the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) that he will not stand for re-election to the Board of the Company at the 2024 Annual Meeting of Shareholders. The Board also set the number of directors at ten, effective immediately after the 2024 Annual Meeting of…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024. Mr. Holzer, 48, joined the Company in 2001. Most recently, from 2021 to…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b)(c) On April 26, 2023, Bristol Myers Squibb Company (the “Company”) filed a Form 8-K to announce the retirement of Giovanni Caforio, M.D. as Chief Executive Officer and his election as Executive Chairman of the Board of Directors of the Company (the “Board”), effective November 1, 2023, and the appointment of Christopher Boerner, Ph.D. as Chief E…

Other Events. On August 9, 2023, Bristol-Myers Squibb Company (“BMS”) entered into accelerated share repurchase (“ASR”) transactions under agreements with each of Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association and Morgan Stanley & Co. LLC (each, an “ASR Agreement” and collectively, the “ASR Agreements”), to repurchase an aggregate of $4.0 billion (the “Repurchase Price”) of BMS common stock, par value $0.10 per share (the “Common Stock”). The ASR transactions…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On April 26, 2023, Bristol Myers Squibb Company (the “Company”) announced that the Board of Directors of the Company (“Board”) appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023. On May 2, 2023, the Board elected Dr. Bo…

Other Events. As previously announced, on November 20, 2019, Bristol-Myers Squibb Company (the “Company”) acquired Celgene Corporation (“Celgene”) when it consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of January 2, 2019 (“Merger Agreement”), among the Company, Burgundy Merger Sub, Inc., a wholly owned subsidiary of the Company, and Celgene. In connection with the consummation of the transactions contemplated by the Merger Agreement, the Company assume…

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (b) Effective July 3, 2023, Dr. Rupert Vessey, Executive Vice President, Research and Early Development, has decided to leave Bristol-Myers Squibb Company (the “Company”). (e) In connection with his departure, Dr. Vessey will be entitled to (i) severance benefits in accordance with the Company’s Senior Executive Severance Plan, and (ii) (A) pro-rated vesting of Market Share Units (MSUs) and…

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Effective April 25, 2022, Ms. Sharon Greenlees will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Karen Murphy Santiago, Senior Vice President and Controller, will leave the Company by May 1, 2022. Ms. Greenlees , 50, most recently, from July 2021, served as Vice President and Controller, R&D Finance and Operations at AbbVie Inc. and…

Other Events. As previously announced, on November 20, 2019 Bristol-Myers Squibb Company (the “Company”) acquired Celgene Corporation (“Celgene”) when it consummated the transactions contemplated by the Agreement and Plan of Merger, dated as of January 2, 2019 (“Merger Agreement”), among the Company, Burgundy Merger Sub, Inc., a wholly owned subsidiary of the Company, and Celgene. In connection with the consummation of the transactions contemplated by the Merger Agreement, the Company assumed…

Other Events. On December 10, 2021, the Board of Directors of Bristol-Myers Squibb Company (“BMS”) approved, and on February 8, 2022 BMS entered into, accelerated share repurchase (“ASR”) transactions under agreements with Morgan Stanley & Co. LLC, Barclays Bank PLC, Citibank, N.A. and JPMorgan Chase Bank, National Association (each, an “ASR Agreement” and collectively, the “ASR Agreements”) to repurchase an aggregate $5.0 billion (the “Repurchase Price”) of BMS common stock, par value $0.10…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On August 3, 2021, Mr. Michael Bonney resigned from the Board of Directors of Bristol-Myers Squibb Company in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc . Also, effective August 3, 2021, the Board set the number of directors at ten.